Describing differences among populations of thoracic tumors patients under and over 80 years: Data analysis from the SLCG thoracic tumor registry

• Published in: Lung cancer (Amsterdam, Netherlands) Vol. 190; p. 107513
• Main Authors: Provencio, Mariano, Cobo, Manuel, Rodriguez-Abreu, Delvys, Carcereny, Enric, Cantero, Alexandra, Calvo, Virginia, López Castro, Rafael, Bernabé, Reyes, Bosch-Barrera, Joaquim, Massutí, Bartomeu, García Campelo, Rosario, Sánchez-Hernández, Alfredo, Laura Ortega, Ana, Guirado, Maria, del Barco, Edel, Camps, Carlos, Casal-Rubio, Joaquin, Dómine, Manuel, Angeles Sala, Mª, Padilla, Airam, Luís González Larriba, Jose, de Asís Aparisi, Francisco
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier B.V 01.04.2024
• Subjects: Aged; Aged, 80 and over; Aging; Biomarkers; Cancer registry; Data Analysis; Female; Humans; Lung cancer; Lung Neoplasms - epidemiology; Lung Neoplasms - therapy; Male; Molecular profiling; Prospective Studies; Registries; Spain; Targeted therapy; Thoracic Neoplasms - epidemiology; ALK; RET; Targeted therapy; EDC; IHC; Lung cancer; Molecular profiling; EGFR; SD; P25; TTR; Aging; AEMPS; PD-L1; SLCG; CGA; ROS1; WHO; SCLC; NSCLC; OS; CI; ECOG-PS; BRAF; Spain; Cancer registry; FISH; KRAS; NGS; HER2; MET; FGFR1
• ISSN: 0169-5002; 1872-8332; 1872-8332
• DOI: 10.1016/j.lungcan.2024.107513

•There are differences among patients with thoracic tumors under and over 80 years.•In the older age group, are performed less molecular determinations.•There are no differences in biomarker alterations between age groups, except for EGFR.•Biomarker status should be tested in older patients to select the best-targeted therapy. Cancer is a disease of old age; however, most studies usually included minority of patients fit elderly. The purpose is to investigate the clinical characteristics and genetic information of patients with thoracic tumors who are 80 years old or older compared to those under 80 years old. The Thoracic Tumor Registry (TTR) is a Spanish observational, prospective cohort study that included patients diagnosed with thoracic tumors. Data were collected from medical records related to sociodemographic, epidemiological, clinical, molecular/genetic, and treatment outcome variables. The total number of patients, recruited from August 2016 to April 2023, was 26.193 (93,1 % were younger than 80 years and 6,9 % were 80 years or older). In the group of older patients: the male ratio increased (72,9 % vs. 80 %); the number of elderly people who had never smoked or were ex-smokers increased (9,9 % vs. 21,1 % and 44,8 % vs. 61,3 %, respectively) and the number of current smokers decreased (43,3 % vs. 17,5 %); had higher ECOG performance status at diagnosis (for ECOG ≥ 2, 15 % vs. 32,9 %), and there were more patients with previous cancer (17,3 % vs. 28 %). The proportion of men is higher than that of women (73 % vs. 27 % in <80 years and 80 % vs. 20 % in ≥80 years). For all biomarkers, the proportion of patients who had a molecular determination was lower in older patients. There were no differences in terms of alterations in the biomarkers tested; except for EGFR, for which the positivity rate was higher in patients aged 80 years and older (25 % vs. 15,3 %). The proportion of older patients with targeted mutations is higher. So, at least at diagnosis, it should be proceeded in a standard way. Then, when it comes to treatment, comorbidities and patient’s baseline situation should be considered. Clinical Trial Registration: NCT02941458.